China Blood Product Industry Report, 2018-2022

Publisher Name :
Date: 12-Feb-2018
No. of pages: 170

The blood product industry in China develops under stimulation of industry policies and downstream demand. The country recorded total lot release volume of 64.11 million bottles of blood products in 2016, representing a year-on-year rise of 20.4%. After high growth in 2016, the lot release decelerated in 2017 due to two-invoice system (one invoicing for “from pharmaceutical company to primary dealer”, and the other invoicing for “from dealers to hospitals”) with full-year quantity standing at 64.29 million bottles, being on a par with the year-ago level.

Human albumin registered lot release volume of 38.95 million bottles and human immunoglobulin (pH4) for intravenous injection 10.07 million bottles in 2017, down 0.9% and 7.5% from a year ago, respectively, largely due to a slow-down in lot release caused by failure of Gansu Institute of Biological Products in disclosing data on lot release volume of blood products and two-invoice system. Meanwhile, the lot release volume of human prothrombin complex, human hepatitis B immunoglobulin (pH4) for intravenous injection, and human rabies immunoglobulin soared by 26.8%, 46.7% and 36.8%, respectively.

There are over 30 blood product manufacturers in a less concentrated industry in China. Among them, China Biologic Products, Hualan Biological Engineering, Shanghai RAAS Blood Products and Beijing Tiantan Biological Products are more competitive, as they have richer blood product lines and adequate supply of raw materials from plasma stations.

In the future, China’s blood product industry will head for the following three aspects:

1. Faster industry integration, higher concentration: over the years, the rising number of M&A cases among Chinese blood product companies gave a boost to industry integration and concentration.

2. Plasma collection volume and number of plasma stations determine position in industry: number of plasma stations has a direct impact on collection volume, and raw material supply of companies directly hinges on collection volume. In current stage, Beijing Tiantan Biological Products Co., Ltd. has completed assets restructuring, and is hopefully to be the bellwether of the industry for it boasts 49 plasma stations, ranking first in the industry.

3. Companies’ more input on research and development of new products is a boon for higher utilization of plasma: Chinese blood product companies are now racing to develop new products, with the aims of stronger comprehensive strength and higher utilization of plasma to reduce waste.

The report highlights the following:

Analysis on development of China blood product industry, including policies, status quo, market structure, supply & demand, market size and competitive landscape;

Analysis on market segments of China blood product industry, covering human albumin, human immunoglobulin (pH4) for intravenous injection, blood coagulation factor VIII, hepatitis B human immunoglobulin, human immunoglobulin, human prothrombin complex and the like;

Analysis on 15 blood product enterprises, including operation, revenue structure, gross margin, R & D investment, blood product business and development strategy;

Summary & forecast and trends.

China Blood Product Industry Report, 2018-2022

Table of Contents

1. Overview of Blood Products
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features

2. Development of China Blood Product Industry
2.1 Related Policies
2.2 Status Quo
2.3 Market Structure
2.4 Market Supply and Demand
2.4.1 Supply
2.4.2 Demand
2.5 Market Size
2.6 Competition Pattern

3. Market Segments of China Blood Product Industry
3.1 Human Albumin
3.1.1 Development Status
3.1.2 Market Structure
3.1.3 Competition Pattern
3.1.4 Prospects
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
3.2.1 Development Status
3.2.2 Competition Pattern
3.2.3 Prospects
3.3 Coagulation Factor VIII
3.3.1 Development Status
3.3.2 Competition Pattern
3.3.3 Prospects
3.4 Hepatitis B Immunoglobulin
3.4.1 Development Status
3.4.2 Competition Pattern
3.5 Human Immunoglobulin
3.5.1 Development Status
3.5.2 Competition Pattern
3.6 Human Prothrombin Complex
3.6.1 Development Status
3.6.2 Competition Pattern
3.7 Tetanus Immunoglobulin
3.7.1 Development Status
3.7.2 Competition Pattern
3.8 Human Rabies Immunoglobulin
3.8.1 Development Status
3.8.2 Competition Pattern

4. Major Enterprises
4.1 China Biologic Products (CBPO)
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R&D Investment
4.1.6 Blood Products Business
4.1.7 Guizhou Taibang Biological Products Co., Ltd.
4.1.8 Shandong Taibang Biological Products Co., Ltd.
4.1.9 Xi'an Huitian Blood Products Co., Ltd.
4.2 Hualan Biological Engineering Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D Investment
4.2.6 Blood Products Business
4.2.7 Development Strategy
4.3 Shanghai RAAS Blood Products
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D Investment
4.3.6 Blood Products Business
4.3.7 Development Strategy
4.4 Beijing Tiantan Biological Products
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 R&D Investment
4.4.6 Blood Products Business
4.4.7 Development Strategy
4.5 Zhenxing Biopharmaceutical & Chemical
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Major Customers
4.5.6 R&D and Investment
4.5.7 Blood Products Business
4.5.8 Development Strategy
4.6 Jiangxi Boya Bio-Pharmaceutical
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R&D and Investment
4.6.6 Blood Products Business
4.6.7 Development Strategy
4.7 Wuhan ZhongyuanRuide Biological Products
4.7.1 Profile
4.7.2 Operation
4.7.3 Blood Products Business
4.7.4 Development Strategy
4.8 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.8.1 Profile
4.8.2 Blood Products Business
4.9 Shanghai Institute of Biological Products
4.9.1 Profile
4.9.2 Blood Products Business
4.10 Wuhan Institute of Biological Products Co., Ltd.
4.10.1 Profile
4.10.2 Blood Products Business
4.11 Shanxi Kangbao Biological Product
4.11.1 Profile
4.11.2 Blood Products Business
4.12 Green Cross China
4.12.1 Profile
4.12.2 Blood Products Business
4.13 Beijing Bohui Innovation Technology
4.13.1 Profile
4.13.2 Operation
4.13.3 Revenue Structure
4.13.4 Gross Margin
4.13.5 R&D Investment
4.13.6 Blood Products Business
4.13.7 Hebei Da’an Pharmaceutical
4.13.8 Guangdong Weilun Biological Pharmaceutical
4.14 Weiguang Biological Products
4.14.1 Profile
4.14.2 Operation
4.14.3 Revenue Structure
4.14.4 Gross Margin
4.14.5 R&D Investment
4.14.6 Blood Products Business
4.14.7 Development Strategy
4.15 Nanyue Biopharming Corporation Ltd.
4.15.1 Profile
4.15.2 Blood Products Business

5. Summary and Forecast
5.1 Summary
5.2 Development Trend
5.2.1 Industry Integration Speeds Up, Concentration Rises Further
5.2.2 Plasma Collection Volume and Number of Plasma Stations Determine the Status in the Industry
5.2.3 Plasma Volume Increases Progressively
5.2.4 Enterprises Make More Input in R&D of New Products to Sharpen Competitiveness
5.2.5 Comprehensive Utilization of Blood Plasma Gets a Further Rise
5.2.6 Downstream Demand Stimulates the Development of the Industry
5.2.7 Healthcare System Reform Deepens, Gradual Perfection of Medical Insurance System Favors the Development of the Industry

List of Charts

Basic Components of Blood
Plasma Protein Separation Procedure
Classification and Effects of Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products in China and Overseas
Blood Product Industry Chain
Time Length of Plasma Collection and Separation Process
Comparison between Blood Product Enterprises and Chemical & Pharmaceutical Enterprises in Operating Costs and Expenses
Production & Sales Cycle of Blood Products
Main Policies on China Blood Product Industry, 1989-2017
Development History of China Blood Product Industry
Lot Release Volume of Major Blood Products in China, 2014-2017
Blood Product Structure in China (by Lot Release Volume), 2014-2017
Plasma Collection Policies in China vs. USA and European Countries
Per Capita Frequency of Plasma Donation and Plasma Collection Volume in China vs. Euro-America
Number of Plasma Collection Stations and YoY Growth Rate in China, 2008-2017
Plasma Station Approval of Major Blood Product Enterprises in China, 2014-2017
Plasma Collection Volume and YoY Growth Rate in China, 2008-2017
Comparison of Blood Products Covered in Drug Catalogue of National Basic Medical Insurance, 2017-2009
Plasma Supply and Demand in China, 2015-2025E
Comparison between the Price (After Cancellation of Limit Price) of Blood Products and the Original Retail Price Ceiling
Market Size of China Blood Product Industry, 2010-2017
Number of Plasma Stations and Plasma Volume of Major Blood Product Enterprises in China, As of Jan. 2018
Main Products of Major Blood Product Manufacturing Enterprises in China
Revenue of Major Blood Product Enterprises in China, 2013-2017
Net Income of Major Blood Product Enterprises in China, 2013-2017
Revenue from Blood Products Business of Major Blood Product Enterprises in China, 2013-2017
Market Share of China Blood Product Industry (by Enterprise), 2015
Market Share of China Blood Product Industry (by Enterprise), 2016
Market Share of China Blood Product Industry (by Enterprise), 2017
Lot Release Volume and YoY Growth Rate of Human Albumin in China, 2010-2017
Proportion of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2017
Market Share of Human Albumin in China (by Lot Release Volume), 2017
Market Share of Human Albumin in China (by Lot Release Volume), 2016
Human Albumin Sales of Major Human Albumin Enterprises in China, 2013-2017
Lot Release Volume of Human Immunoglobulin for Intravenous Injection in China, 2010-2017
Market Share of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2017
Market Share of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2016
Human Immunoglobulin (pH4) for Intravenous Injection Sales of Major Blood Products Enterprises in China, 2013-2017
Lot Release Volume of Blood Coagulation Factor VIII in China, 2010-2017
Market Share of Blood Coagulation Factor VIII in China (by Lot Release Volume), 2017
Lot Release Volume of Hepatitis B Immunoglobulin in China, 2010-2017
Market Share of Hepatitis B Immunoglobulin in China (by Lot Release Volume), 2017
Lot Release Volume of Human Immunoglobulin in China, 2010-2017
Market Share of Human Immunoglobulin in China (by Lot Release Volume), 2017
Lot Release Volume of Human Prothrombin Complex in China, 2010-2017
Market Share of Human Prothrombin Complex in China (by Lot Release Volume), 2017
Lot Release Volume of Tetanus Immunoglobulin in China, 2010-2017
Market Share of Tetanus Immunoglobulin in China (by Lot Release Volume), 2017
Lot Release Volume of Human Rabies Immunoglobulin in China, 2010-2017
Market Share of Human Rabies Immunoglobulin in China (by Lot Release Volume), 2017
Product Line of CBPO
Revenue and Operating Income of CBPO, 2012-2017
Revenue Breakdown of CBPO (by Product), 2012-2017
Revenue Structure of CBPO (by Product), 2012-2017
Gross Margin of CBPO, 2012-2017
R&D Costs and % of Total Revenue of CBPO, 2012-2017
CBPO’s Products under Research and R&D Process by the end of 2016
Lot Release Volume of Blood Products of CBPO, 2015-2017
Main Plasma Collection Stations of Guizhou Taibang Biological Products as of Jan. 2018
Lot Release Volume of Blood Products of Guizhou Taibang Biological Products, 2016-2017
Ownership Structure of Shandong Taibang Biological Products
Main Plasma Collection Stations of Shandong Taibang Biological Products as of Jan. 2018
Lot Release Volume of Blood Products of Shandong Taibang Biological Products, 2016-2017
Ownership Structure of Xi'an Huitian Blood Products
Main Plasma Collection Stations of Xi'an Huitian Blood Products as of 2018
Revenue and Net Income of Hualan Biological Engineering, 2013-2017
Revenue Breakdown of Hualan Biological Engineering (by Product), 2013-2017
Revenue Structure of Hualan Biological Engineering (by Product), 2013-2017
Gross Margin of Blood Products of Hualan Biological Engineering (by Product), 2013-2017
R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2013-2017
Category and Specification of Blood Products of Hualan Biological Engineering
Revenue of Blood Products of Hualan Biological Engineering, 2013-2017
Lot Release Volume of Blood Products of Hualan Biological Engineering, 2015-2017
Revenue and Net Income of Hualan Biological Engineering, 2016-2022E
Revenue and Net Income of Shanghai RAAS Blood Products, 2013-2017
Revenue Breakdown of Shanghai RAAS Blood Products (by Product), 2013-2017
Revenue Breakdown of Shanghai RAAS Blood Products (by Region), 2013-2017
Revenue Structure of Shanghai RAAS Blood Products (by Region), 2013-2017
Gross Margin of Shanghai RAAS Blood Products (by Product), 2013-2017
R&D Costs of Shanghai RAAS Blood Products, 2013-2017
Blood Products of Shanghai RAAS Blood Products and Its Subsidiaries
Lot Release Volume of Blood Products of Shanghai RAAS Blood Products, 2015-2017
Revenue and Net Income of Shanghai RAAS Blood Products, 2016-2022E
Revenue and Net Income of Tiantan Biological Products, 2013-2017
Revenue Breakdown of TIANTANBIO (by Product), 2013-2016
Revenue Structure of TIANTANBIO (by Product), 2013-2016
Revenue Breakdown of TIANTANBIO (by Region), 2013-2016
Revenue Structure of TIANTANBIO (by Region), 2013-2016
Gross Margin of TIANTANBIO (by Product), 2013-2016
R&D Costs and % of Total Revenue of TIANTANBIO, 2013-2017
R&D Input of Major Projects of TIANTANBIO, 2016
Progress of Major R&D Projects of TIANTANBIO, by the End of 2016
Main Content of Assets Restructuring of Beijing Tiantan Biological Products
Revenue and Net Income of Chengdu Rongsheng, 2015-2017
Lot Release Volume of Main Blood Products of Chengdu Rongsheng, 2015-2017
Revenue and Net Income of TIANTANBIO, 2017-2022E
Revenue and Net Income of Zhenxing Biopharmaceutical & Chemical, 2013-2017
Revenue Breakdown of Zhenxing Biopharmaceutical & Chemical (by Product), 2013-2017
Revenue Structure of Zhenxing Biopharmaceutical & Chemical (by Product), 2013-2017
Gross Margin of Zhenxing Biopharmaceutical & Chemical, 2013-2017
Zhenxing Biopharmaceutical & Chemical’s Sales from Top 5 Customers, 2014-2016
R&D Costs and % of Total Revenue of Zhenxing Biopharmaceutical & Chemical, 2013-2017
Use of Funds Raised by Zhenxing Biopharmaceutical & Chemical through Private Issuing of A Shares, 2016
Revenue and Net Income of Shuanglin Bio-Pharmacy, 2014-2017
Production-use Plasma Volume of Guangdong Shuanglin Bio-Pharmacy, 2013-2016
Lot Release Volume of Blood Products of Guangdong Shuanglin Bio-Pharmacy, 2015-2017
Output, Sales Volume and Inventory of Blood Products of Zhenxing Biopharmaceutical & Chemical, 2013-2016
Revenue and Net Income of Zhenxing Biopharmaceutical & Chemical, 2016-2022E
Revenue and Net Income of Jiangxi Boya Bio-Pharmaceutical, 2013-2017
Revenue Breakdown of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2017
Revenue Structure of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2017
Gross Margin of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2016
Gross Margin of Main Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2013-2017
R&D Costs of Jiangxi Boya Bio-Pharmaceutical, 2013-2017
New Patents of Jiangxi Boya Bio-Pharmaceutical, 2017
Revenue of Jiangxi Boya Bio-Pharmaceutical by Product, 2015-2017
Lot Release Volume of Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2017
Revenue and Net Income of Jiangxi Boya Bio-Pharmaceutical, 2016-2022E
Development Course of ZhongyuanRuide Biological Products
Financial Data of Zhongyuan Ruide, 2014-2016
Main Plasma Collection Stations of ZhongyuanRuide Biological Products, as of Jan. 2018
Lot Release Volume of Blood Products of ZhongyuanRuide Biological Products, 2016-2017
Development History of Sichuan Yuanda Shuyang Pharmaceutical
Specification of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical
Lot Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical, 2016-2017
Plasma Collection Stations of Shanghai Institute of Biological Products as of Jan. 2018
Specification of Main Blood Products of Shanghai Institute of Biological Products
Lot Release Volume of Blood Products of Shanghai Institute of Biological Products, 2016-2017
Plasma Collection Stations of Wuhan Institute of Biological Products, as of Jan. 2018
Lot Release Volume of Blood Products of Wuhan Institute of Biological Products, 2016-2017
Plasma Collection Stations of Shanxi Kangbao Biological Product as of Jan. 2018
Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2016-2017
Plasma Collection Stations of Green Cross China as of Jan. 2018
Lot Release Volume of Blood Products of Green Cross China, 2016-2017
Revenue and Net Income of Beijing Bohui Innovation Technology, 2014-2017
Revenue of Beijing Bohui Innovation Technology by Product, 2014-2017
Revenue Structure of Beijing Bohui Innovation Technology by Product, 2014-2017
Gross Margin of Beijing Bohui Innovation Technology by Product, 2014-2017
R&D Costs and % of Total Revenue of Beijing Bohui Innovation Technology, 2014-2017
Progress of Major Blood Product R&D Projects of Beijing Bohui Innovation Technology, as of 2017H1
Major Blood Products of Beijing Bohui Innovation Technology
Output, Sales Volume and Inventory of Blood Products of Beijing Bohui Innovation Technology, 2015-2016
Plasma Collection Stations of Hebei Da’an Pharmaceutical, as of Jan. 2018
Revenue and Net Income of Hebei Da’an Pharmaceutical, 2015-2017
Lot Release Volume of Blood Products of Hebei Da’an Pharmaceutical, 2016-2017
Plasma Collection Stations of Guangdong Weilun Biological Pharmaceutical, as of Jan.2018
Lot Release Volume of Blood Products of Guangdong Weilun Biological Pharmaceutical, 2016-2017
Revenue and Net Income of Shenzhen Weiguang Biological Products, 2014-2017
Revenue Breakdown and Structure of Shenzhen Weiguang Biological Products (by Product), 2014-2017
Revenue Breakdown and Structure of Shenzhen Weiguang Biological Products (by Region), 2014-2016
Gross Margin of Shenzhen Weiguang Biological Products, 2014-2016
Gross Margin of Shenzhen Weiguang Biological Products (by Product), 2014-2016
R&D Costs and % of Total Revenue of Shenzhen Weiguang Biological Products, 2014-2017
R&D Process of Products under Research of Shenzhen Weiguang Biological Products, as of 2017H1
Fundraising Projects of Shenzhen Weiguang Biological Products, 2017
Financial Data of Plasma Collection Stations of Shenzhen Weiguang Biological Products, 2017H1
Plasma Collection Volume of Shenzhen Weiguang Biological Products, 2014-2016
Capacity, Output and Sales Volume of Major Products of Shenzhen Weiguang Biological Products, 2014-2016
Average Sales Price of Major Products of Shenzhen Weiguang Biological Products, 2014-2016
Lot Release Volume of Blood Products of Shenzhen Weiguang Biological Products, 2016-2017
Revenue and Net Income of Shenzhen Weiguang Biological Products, 2016-2022E
Plasma Collection Stations of Nanyue Biopharming, as of Jan.2018
Lot Release Volume of Blood Products of Nanyue Biopharming, 2016-2017
Market Size of Blood Products in China, 2017-2022E
M&A Cases of Foreign Blood Product Companies
M&A Cases in China Blood Product Industry, 2008-2017
Plasma Collection Volume and YoY Change in China, 2017-2022E
R&D Investments of Major Chinese Blood Product Enterprises, 2013-2017
New Products Being Developed of Major Chinese Blood Product Enterprises

  • United States Blood Banking Market by Manufacturers, States, Type and Application, Forecast to 2022
    Published: 10-May-2018        Price: US 4480 Onwards        Pages: 116
    This report studies the Blood Banking market, and blood banking refers to the process of collecting, separating, and storing blood. A blood bank is a center where blood gathered as a result of blood donation is stored and preserved for later use in blood transfusion. The term "blood bank" typically refers to a division of a hospital where the storage of blood product occurs and where proper testing is performed (to reduce the risk of transfusion related adverse events). However, it sometimes ref......
  • Global and United States Blood Bank Market Research by Company, Type & Application 2013-2025
    Published: 29-Apr-2018        Price: US 2000 Onwards        Pages: 107
    Summary Market Segment as follows: By Type - Type 1 - Type 2 - Type 3 By Application - Hospitals - Laboratories - Blood Centers - Others By Company - Panasonic Biomedical - Dometic - Thermo Fisher Scientific - Vestfrost Solutions - Follett - Helmer Scientific - Norlake scientific - GEM Scientific - Telstar - Summit - SO......
  • Global and United States Blood Product Market Research by Company, Type & Application 2013-2025
    Published: 28-Apr-2018        Price: US 2000 Onwards        Pages: 85
    Summary Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called blood product. Market Segment as follows: By Type - Albumin - Immune Globulin - Coagulation Factor - Others By Application - Immunity - Therapy - Surgery - Others......
  • Global Cord Blood Banking Service Market Size, Status and Forecast 2025
    Published: 26-Apr-2018        Price: US 3300 Onwards        Pages: 114
    This report studies the global Cord Blood Banking Service market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Cord Blood Banking Service market by companies, region, type and end-use industry. This report focuses on the global top players, covered - America Cell Biobank, Inc. - Banco de Cordon Umbilical (BCU) - Cord Blood America, Inc. - Cellpreserve - CrioCenter......
  • China Blood Products Market Research Report 2018
    Published: 30-Mar-2018        Price: US 3400 Onwards        Pages: 100
    The global Blood Products market is valued at XX million USD in 2017 and is expected to reach XX million USD by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. China plays an important role in global market, with market size of xx million USD in 2017 and will be xx million USD in 2025, with a CAGR of xx%. This report studies the Blood Products development status and future trend in China, focuses on top players in China, also splits Blood Products b......
  • Blood Products Companies in China
    Published: 26-Mar-2018        Price: US 1800 Onwards        Pages: 81
    This study focuses on China's Blood Products industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of ......
  • Blood Products Markets in China
    Published: 26-Mar-2018        Price: US 4000 Onwards        Pages: 274
    China's demand for Blood Products has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, indust......
  • Blood Products Industry Forecasts - China Focus
    Published: 26-Mar-2018        Price: US 1800 Onwards        Pages: 144
    This study focuses on China's Blood Products industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and services. The......
  • Global Blood Products Market Professional Survey Report 2018
    Published: 23-Mar-2018        Price: US 3500 Onwards        Pages: 105
    This report studies Blood Products in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2013 to 2018, and forecast to 2025. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Baxter - CSL - Grifols - Octapharma - BPL - Kedrion......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs